TrialBritish journal of clinical pharmacology2020

Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants.

Ian M Catlett et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.